Understanding the presence and function of erythropoietin receptors on cancer cells.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-10-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1200/JCO.2006.08.1190PMID 17028292
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidermal growth factor receptor biology in head and neck cancer.

  2006cited by this paper
• Erythropoietin Biology in Cancer

  2006cited by this paper
• Do erythropoietin receptors on cancer cells explain unexpected clinical findings?

  2006cited by this paper
• Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells

  2006cited by this paper
• Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.

  2005cited by this paper
• Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models.

  2005cited by this paper
• New avenues of exploration for erythropoietin.

  2005cited by this paper
• Erythropoietin Promotes MCF-7 Breast Cancer Cell Migration by an ERK/Mitogen-activated Protein Kinase-dependent Pathway and Is Primarily Responsible for the Increase in Migration Observed in Hypoxia*

  2005cited by this paper
• The anaemia of cancer: death by a thousand cuts

  2005cited by this paper
• Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

  2005cited by this paper
• Mechanisms of erythropoietin‐mediated cardioprotection during ischemia‐reperfusion injury: role of protein kinase C and phosphatidylinositol 3‐kinase signaling

  2005cited by this paper
• Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma

  2005cited by this paper
• The erythropoietin-receptor pathway modulates survival of cancer cells

  2004cited by this paper
• Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin.

  2004cited by this paper
• Erythropoietin to treat anaemia in patients with head and neck cancer.

  2004cited by this paper
• Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.

  2003cited by this paper
• Erythropoietin regulates tumour growth of human malignancies.

  2003cited by this paper
• Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.

  2003cited by this paper
• Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.

  2002cited by this paper
• Erythropoietin and G-csf Receptors in Human Tumor Cells: Expression and Aspects regarding Functionality

  2002cited by this paper
• Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.

  2002cited by this paper
• Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review.

  2001cited by this paper
• Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models

  2001cited by this paper
• Anemia as an independent prognostic factor for survival in patients with cancer

  2001cited by this paper
• The negative impact of anemia on radiotherapy and chemoradiation outcomes.

  2001cited by this paper
• Activation of the transcription factor NF-kappaB by the erythropoietin receptor: structural requirements and biological significance.

  2001cited by this paper
• Activation of the transcription factor NF-?B by the erythropoietin receptor

  2001cited by this paper
• In vivo evidence that erythropoietin protects neurons from ischemic damage.

  1998cited by this paper
• Estrogen-dependent Production of Erythropoietin in Uterus and Its Implication in Uterine Angiogenesis*

  1998cited by this paper
• Decreased erythropoietin response in patients with the anemia of cancer.

  1990cited by this paper
• Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells.

  1990cited by this paper

• Pre-treatment anemia in head and neck cancer: risk factors, subtypes, and survival outcomes

  2025cites this paper
• Anemia of Chronic Diseases: Wider Diagnostics—Better Treatment?

  2020cites this paper
• Activated platelets induce hypoxia-inducible factor-1α expression likely through transforming growth factor-β1 in human endometrial stromal cells

  2019cites this paper
• Application of biosensors in cancer research

  2018influential citation
• Clinicopathological factors associated with novel prognostic markers for patients with triple negative breast cancer

  2018cites this paper
• Immunohistochemical expression of erythropoietin in invasive breast carcinoma with metastasis to lymph nodes

  2018cites this paper
• Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins

  2016cites this paper
• Introduction Erythropoietin receptor and tissue factor are coexpressed in human breast cancer cells

  2015cites this paper
• Erythropoietin receptor and tissue factor are coexpressed in human breast cancer cells.

  2015cites this paper
• Autocrine/paracrine erythropoietin regulates migration and invasion potential and the stemness of human breast cancer cells

  2014cites this paper
• Risk of venous thromboembolism with the erythropoiesisstimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials

  2013cites this paper
• Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis

  2013cites this paper
• Hematopoietic growth factors: Personalization of risks and benefits

  2012cites this paper
• Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials.

  2012cites this paper
• Treating patients with schizophrenia deficit with erythropoietin?

  2012cites this paper
• The VHL-HIF Signaling in Renal Cell Carcinoma: Promises and Pitfalls

  2012cites this paper
• 3 The VHL-HIF Signaling in Renal Cell Carcinoma : Promises and Pitfalls

  2012cites this paper
• Hypoxia Induces Erythropoietin Receptor Expression on K562 Cell Line

  2011cites this paper
• Novel Avenues of Drug Discovery and Biomarkers for Diabetes Mellitus

  2011cites this paper
• Oxidative stress: Biomarkers and novel therapeutic pathways

  2010cites this paper
• Novel Strategies for Neurovascular Longevity During Aging

  2010cites this paper
• Expression of Erythropoietin and Its Receptor in Human Renal Cell Carcinoma

  2009cites this paper
• Retrospective review of hemoglobin and/or hematocrit levels with occurrence of thrombosis in cancer patients treated with erythropoiesis stimulating agents

  2009cites this paper
• Erythropoietin, Forkhead Proteins, and Oxidative Injury: Biomarkers and Biology

  2009cites this paper
• Erythropoietin inhibits respiratory epithelial cell apoptosis in a model of acute lung injury

  2009cites this paper
• Regenerative medicine: does Erythropoietin have a role?

  2009cites this paper
• Down with the erythropoietin. Long live the erythropoietin!

  2009cites this paper
• Title: Erythropoietin inhibits respiratory epithelial cell apoptosis in a model of ALI. Running title: EPO: cytoprotective in lung epithelium.

  2009cites this paper
• Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events.

  2009influential citation
• Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus.

  2008cites this paper
• Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.

  2008cites this paper
• Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle.

  2008cites this paper
• Increased Levels of Erythropoietin in Nipple Aspirate Fluid and in Ductal Cells from Breast Cancer Patients

  2008cites this paper
• Erythropoietin receptors on tumor cells: what do they mean?

  2008cites this paper
• FDA Releases Draft Guidance on Regulation of Genetically Engineered Animals

  2008cites this paper
• Recombinant adenovirus as a methodology for exploration of physiologic functions of growth factor pathways

  2008cites this paper
• Erythropoietin and oxidative stress.

  2008cites this paper
• Practice and costs of red blood cell (RBC) transfusion in an oncological unit.

  2008cites this paper
• Erythropoietin in cancer: the new face of an old friend.

  2008cites this paper
• Comment: Research, regulatory trends suggest ESAs should play declining role in patient care

  2008cites this paper
• Treating Cancer Patients with Erythropoietin: Better Safe than Sorry

  2008cites this paper
• Role of Erythropoietin in Cancer-related Anaemia: A Double-edged Sword?

  2008cites this paper
• Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies.

  2008cites this paper
• Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin.

  2007cites this paper
• Erythropoietin and Erythropoietin Receptor Coexpression Is Associated with Poor Survival in Stage I Non–Small Cell Lung Cancer

  2007cites this paper
• Are erythropoietin receptors expressed in tumors? Facts and fiction--more careful studies are needed.

  2007cites this paper
• Recombinant human erythropoietin in treatment of the cancer patients with anemia: hopes and threats

  2007cites this paper
• Erythropoietin: high profile, high scrutiny.

  2007cites this paper
• Expression of erythropoietin and its receptor in neuroblastomas

  2007cites this paper